Total amount raised
$496 Millions
Latest funding date
12/01/2024
Location
Maze Therapeutics has successfully raised $115 million in its latest financing round, supporting the advancement of its clinical-stage programs and future pipeline development. The company focuses on developing precision medicines for renal, cardiovascular, and metabolic diseases, leveraging advances in human genetics and biological processes.
Keep reading to explore the intricacies of Maze Therapeutics' fundraising journey and the investors backing this innovative platform.
What Is Maze Therapeutics?
Maze Therapeutics, founded on August 29, 2017, is a biotechnology company based in South San Francisco, California. The company operates in the biopharma, biotechnology, genetics, and therapeutics industries.
Founded by Aaron Gitler, Charles Homcy, Jonathan Weissman, Mark Daly, Sekar Kathiresan, and Stephen Elledge, Maze Therapeutics employs between 101 and 250 people. The company focuses on developing precision medicines for renal, cardiovascular, and metabolic diseases, leveraging advances in human genetics and biological processes.
How Much Funding Has Maze Therapeutics Raised?
- Series A
- Amount Raised: $191M
- Date: February 2019
- Lead Investors: ARCH Venture Partners, Third Rock Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support the company's mission to translate genetic insights into new medicines.
- Venture Round
- Amount Raised: Not disclosed
- Date: October 2019
- Lead Investors: City Hill Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: Likely aimed at advancing research and development efforts.
- Venture Round
- Amount Raised: $190M
- Date: January 2022
- Lead Investors: Matrix Capital Management
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand the product pipeline and bring new precision medicines to market.
- Series D
- Amount Raised: $115M
- Date: December 2024
- Lead Investors: Deep Track Capital, Frazier Life Sciences
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To advance clinical-stage programs and future pipeline development.
Total Amount Raised: $496M. Current Valuation: Not publicly disclosed.
Key Investors
- Third Rock Ventures
- Details: Third Rock Ventures is a venture capital firm focused on building innovative life sciences companies. They have a strong track record of partnering with entrepreneurs to bring transformative healthcare solutions to market.
- Investment Focus Areas: Life sciences, biotechnology, healthcare
- Notable Investments: Bluebird Bio, Editas Medicine, Foundation Medicine
- ARCH Venture Partners
- Details: ARCH Venture Partners is a venture capital firm that invests in the development of seed and early-stage advanced technology companies. They are known for their deep expertise in the life sciences sector.
- Investment Focus Areas: Advanced technology, life sciences, biotechnology
- Notable Investments: Illumina, Alnylam Pharmaceuticals, Juno Therapeutics
- GV (formerly Google Ventures)
- Details: GV is the venture capital investment arm of Alphabet Inc., investing in various sectors including life sciences. They leverage Google's resources to support their portfolio companies.
- Investment Focus Areas: Life sciences, technology, healthcare
- Notable Investments: Uber, Slack, Flatiron Health
- Foresite Capital
- Details: Foresite Capital is a healthcare and life sciences investment firm. They focus on identifying and supporting companies with the potential to transform healthcare.
- Investment Focus Areas: Healthcare, life sciences
- Notable Investments: 10X Genomics, Denali Therapeutics, Relay Therapeutics
- Casdin Capital
- Details: Casdin Capital is an investment firm focused on life sciences and healthcare. They aim to support companies that are at the forefront of scientific innovation.
- Investment Focus Areas: Life sciences, healthcare
- Notable Investments: Twist Bioscience, Invitae, Adaptive Biotechnologies
What's Next for Maze Therapeutics?
Maze Therapeutics stands at the forefront of translating genetic insights into new medicines, leveraging substantial funding and the expertise of renowned scientists. The company is poised to capitalize on the growing interest in personalized medicine and genetic research, with opportunities to develop groundbreaking treatments for renal, cardiovascular, and metabolic diseases.
Future fundraising prospects appear promising, given the involvement of high-profile investors like Third Rock Ventures and ARCH Venture Partners. These relationships could pave the way for additional funding rounds, enabling Maze Therapeutics to expand its research capabilities and product pipeline.
However, the path ahead is not without challenges. The biotech sector is highly competitive, and regulatory hurdles for new medicines can be significant. Despite these obstacles, Maze Therapeutics' strong financial backing and strategic partnerships position it well for future growth and innovation.
Use Clay to Get Funding Data
Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like Maze Therapeutics and gather other critical business insights. Sign up for free to start transforming your sales strategy today.
